RCT | Multiple sclerosis disease-modifying therapy continuation versus discontinuation in older individuals

Risk of new disease activity in patients with multiple sclerosis who continue or discontinue disease-modifying therapies (DISCOMS): a multicentre, randomised, single-blind, phase 4, non-inferiority trial – The Lancet Neurology (link to abstract – $ for full-text)

Commentaries:

Study investigates risk when discontinuing therapy for MS patients over 55 – CU Anschutz Medical Campus

Discontinuing Multiple Sclerosis Therapies at Age 55 or Older – NEJM Journal Watch